Sign In
Buy CELC
$88.95
-2.47 (-2.70%)
At Close: Jun 03, 2026
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
10:13pm, Wednesday, 03'rd Jun 2026
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) ("Celcuity" or the "Company"), a clinical-stage biotechnology company focused on the development of targeted therapies for t
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
10:13pm, Wednesday, 03'rd Jun 2026
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapi
Celcuity: Selloff On Yesterday's Data Unwarranted - Buy Rating Upheld
09:33am, Wednesday, 03'rd Jun 2026
Celcuity (CELC) shares dropped over 25% despite Phase 3 VIKTORIA-1 data confirming gedatolisib's best-in-class efficacy in advanced breast cancer. Gedatolisib demonstrated superior progression-free su
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
07:19am, Wednesday, 03'rd Jun 2026
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) ("Celcuity" or the "Company"), a clinical-stage biotechnology company focused on the development of targeted therapies for t
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
07:19am, Wednesday, 03'rd Jun 2026
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapi
Celcuity Inc. (CELC) Discusses VIKTORIA-1 Trial Results for PIK3CA Mutant Advanced Breast Cancer and Gedatolisib Efficacy Transcript
04:11pm, Tuesday, 02'nd Jun 2026
Celcuity Inc. (CELC) Discusses VIKTORIA-1 Trial Results for PIK3CA Mutant Advanced Breast Cancer and Gedatolisib Efficacy Transcript
What's Going On With Celcuity Stock On Tuesday?
01:37pm, Tuesday, 02'nd Jun 2026
Celcuity Inc. (NASDAQ:CELC) on Tuesday reported detailed efficacy and safety findings from the PIK3CA-mutated cohort of its Phase 3 VIKTORIA-1 trial.
Celcuity plunges after experimental breast cancer treatment data disappoints
01:20pm, Tuesday, 02'nd Jun 2026
Celcuity shares slumped 25% , set for their biggest one-day decline, on Tuesday after its experimental breast cancer treatment extended the period of time a patient lives without the disease wor
Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer
08:25am, Tuesday, 02'nd Jun 2026
MINNEAPOLIS, June 02, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple sol
MINNEAPOLIS, June 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid
Celcuity To Participate in Upcoming Investor Conferences
08:30am, Thursday, 28'th May 2026
MINNEAPOLIS, May 28, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid
Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst
01:13pm, Friday, 15'th May 2026
On Thursday, Celcuity Inc. (NASDAQ:CELC) announced amendments to its Phase 3 VIKTORIA-2 clinical trial evaluating gedatolisib as a first-line treatment for patients with hormone receptor-positive, HER
Celcuity Inc. (CELC) Q1 2026 Earnings Call Transcript
08:20pm, Thursday, 14'th May 2026
Celcuity Inc. (CELC) Q1 2026 Earnings Call Transcript
Celcuity Q1 Earnings Call Highlights
07:11pm, Thursday, 14'th May 2026
Celcuity NASDAQ: CELC reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its investiga
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
04:01pm, Thursday, 14'th May 2026
MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid
